[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,78,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100054125","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100054125",false,"NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE","18 Years",{"count":20,"type":21},115,"ESTIMATED","OBSERVATIONAL","We therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Chemotherapy","Radiotherapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[40,41,42],"Comparative","observational","retrospective","NOT_YET_RECRUITING","2026-07-07",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-07-10",{"date":51,"type":21},"2026-08-20",{"name":53,"class":54},"University Hospital, Grenoble","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100571266","the-association-between-age-related-peripheral-blood-components-and-treatment-efficacy-in-breast-cancer-100571266","NCT06718010","The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer","Age-Related Peripheral Blood Components and Their Association With Treatment Efficacy in Breast Cancer Patients: An Observational Cohort Study","Inclusion Criteria:\n\n1. Signed informed consent according to local regulations;\n2. Age ≥ 18 years;\n3. Female;\n4. Histologically\u002Fcytologically confirmed breast cancer;\n5. Determined by immunohistochemistry to be ER+ or PR+ (with at least 1% of cells expressing estrogen receptors) and HER2-.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis;\n2. History of other malignancies. Patients with basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, or other cancers who have been disease-free for more than 5 years after appropriate treatment may be included;\n3. Participation in another clinical trial within 30 days prior to starting neoadjuvant treatment for breast cancer, and receiving investigational drugs or any concomitant treatment including investigational drugs;\n4. Immunodeficiency or HIV infection;\n5. Severe heart, lung, liver, or kidney dysfunction;\n6. Uncontrolled infections or active infections;\n7. Pregnant or breastfeeding women.",{"count":63,"type":21},120,"This study is a single-center, prospective\u002Fretrospective, observational clinical research designed to compare the differences in peripheral blood components between young and elderly HR+HER2- breast cancer patients, and to identify peripheral blood components that may affect the prognosis of young HR+HER2- breast cancer patients.\n\nThe study population consists of early-stage HR+HER2- breast cancer patients receiving neoadjuvant therapy. Eligible patients who require neoadjuvant treatment will be enrolled in the study. Retrospective data and samples will be collected based on existing patient medical records and tissue biobank samples. Prospective data collection will be based on routine clinical treatment during the study period and will continue until the patient completes neoadjuvant therapy and undergoes primary tumor surgery, or until the study is prematurely terminated.\n\nHR+HER2- breast cancer patients receiving neoadjuvant therapy will be divided into young and elderly groups. Peripheral blood samples will be collected at baseline (T0, prior to treatment) and after two cycles of neoadjuvant therapy (T1). Paired baseline tumor biopsy samples and\u002For surgical tumor samples will also be collected. Peripheral blood and tumor samples will undergo appropriate tests.\n\nThe study respects the investigator's choice of treatment, without specifying which drugs should be used, the dosage, the administration mode (including monotherapy, combination therapy, or sequential therapy), or the duration of treatment.",[66,26],"Breast Cancer","RECRUITING","2026-01-20",{"date":70,"type":47},"2026-01-21",{"date":72,"type":47},"2024-12-05",{"date":74,"type":21},"2026-03-31",{"name":76,"class":54},"Fudan University",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":77},"100555627","phase-4-vaccine-immunity-and-inflammation-in-the-aging-person-living-with-hiv-100555627","NCT06514547","Vaccine Immunity and Inflammation in the Aging Person Living With HIV","VIVID","Inclusion Criteria:\n\n* Age\\>=18 years\n* HIV Diagnosis\n* On Antiretroviral Therapy with HIV Viral Load\\\u003C200 within last year\n\nExclusion Criteria:\n\n* Other significant immunosuppressing condition\n* Age\\\u003C 18 years\n* Pregnancy (at enrollment)\n* Contraindication to pneumococcal vaccination\n* Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \\\u003C8g\u002Fdl)\n* Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures.\n* Adults unable to consent\n* Individuals with impaired ability to consent\n* Incarceration at time of enrollment\n\nControls inclusion criteria:\n\n* Age\\>=18 years\n* HIV Ag-Ab test negative",true,"ALL",{"count":88,"type":21},250,"INTERVENTIONAL",[91],"PHASE4","This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.",[94,26],"HIV Infections","2025-06-09",{"date":97,"type":47},"2025-06-12",{"date":99,"type":47},"2024-07-08",{"date":101,"type":21},"2029-06-30",{"name":103,"class":54},"Hennepin Healthcare Research Institute",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":85,"sex":86,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":89,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":77},"100587950","ethanol-consumption-in-the-heat-100587950","NCT06935045","Ethanol Consumption in the Heat","Evaluating How Alcohol Impacts Physiological Responses and Perception During Heat Exposure","Inclusion Criteria:\n\n* Male or Female above the age of 19\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of cardiovascular disease, cancer, type 1 or 2 diabetes, chronic obstructive pulmonary disorder, cystic fibrosis, or alcohol addiction or dependence\n* Been hospitalized due to COVID-19\n* Pregnant\u002FBreastfeeding\n* Scoring an eight or above on the Alcohol Use Disorders Identification Test (AUDIT)","19 Years",{"count":113,"type":21},34,[115],"NA","Climate change has significantly increased the earth's average surface temperature and heat waves have been predicted to increase in frequency, intensity and duration. Extreme heat events have increased the susceptibility to heat-related illnesses, such as heat exhaustion, heat stroke or death. Heat health action plans have been designed to advertise cooling behaviours to mitigate physiological strain. Heat health action plans suggest avoiding alcohol consumption during extreme heat as it may increase dehydration and impair behavioural or physiological temperature regulation and thermal perception. Regardless of these messages, alcohol sales continue to remain high during the summer months year after year, and 1\u002F5 of adults identify alcohol as a hydration strategy during extreme heat events. A recent scoping review investigating the effects of alcohol and heat has demonstrated that acute alcohol consumption does not negatively influence thermoregulation, hydration, or hormone markers of fluid balance in the heat compared to a control fluid (https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12940-024-01113-y). Further, alcohol consumption may elicit sex- and age-specific alterations in physiological and perceptual responses, neither of which have been explored.\n\nTherefore, this study aims to comprehensively evaluate how alcohol consumption systematically alters physiological responses and perceptions during conditions similar to those experienced indoors during extreme heat events in younger and older adults.",[118,119,26],"Alcohol Consumption","Heat Stress",[121,122,123,124,125,126,127,128],"alcohol","heat stress","heat wave","sweating","core temperature","micturition","perception","behaviour","2025-04-11",{"date":131,"type":47},"2025-04-18",{"date":133,"type":47},"2023-12-04",{"date":135,"type":21},"2025-08",{"name":137,"class":54},"Lakehead University"]